First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis
Status:
Completed
Trial end date:
2011-09-09
Target enrollment:
Participant gender:
Summary
The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline
to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS).
The drug works by inhibiting the protein that prevents nerve growth.
This will be the first time the drug will be given to man. The trial is expected to involve
approximately 76 patients. The study objective is to investigate the tolerability, safety and
the way the body handles GSK1223249 after a range of single doses or repeat dose escalation
in patients with ALS.